What is Rigel Pharmaceuticals's royalty — revenue recognized?

Rigel Pharmaceuticals (RIGL) reported royalty — revenue recognized of $1.8M in Q1 2026.

What does royalty — revenue recognized mean?

This metric represents the total revenue recognized from royalty payments earned through the licensing of intellectual property or drug candidates to third-party partners. It reflects the company's ability to monetize its research and development pipeline by outsourcing commercialization while retaining a percentage of net sales. This is a key indicator of the long-term commercial viability of the company's licensed assets.

Rigel Pharmaceuticals (RIGL) Royalty — Revenue recognized

Screener

Other product segments

Gross product sales

$75.39M+25.2%

Release Of Share Cost Liability

$39.98M—

Discounts and allowances

-$20.47M-23.0%

Delivery of drug supplies, royalties and others

$3.9M-42.6%

Development Milestones

$0-100%

Similar metrics at other companies

MCOTransaction Revenue — Revenue recognized

$901M+28.9%

MCORecurring Revenue — Revenue recognized

$1.28B+7.1%

MCOCMBS — Revenue recognized

$25M0.0%

MCOKYC — Revenue recognized

$121M+13.1%

MCORMBS — Revenue recognized

$35M+20.7%

MCOBanking — Revenue recognized

$148M+23.3%

Other financials

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

See full

Market cap$750.37M+25.0%

Enterprise value$794.27M+44.9%

P/E2.1×-4.1×

P/S2.5×+0.3×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed: May 5, 2026, 4:05 PM EDT
Fiscal quarter: Q4 FY2026
Calendar quarter: Q4 2026
Accession: 0001034842-26-000032

We also recognize royalty revenue from Grifols included within contract revenues from this collaboration. Royalty revenue for the three months ended March 31, 2026 and 2025 from Grifols was $1.8 million and $1.4 million, respectively.

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's royalty — revenue recognized?: Rigel Pharmaceuticals (RIGL) reported royalty — revenue recognized of $1.8M in Q1 2026.
What does royalty — revenue recognized mean?: This metric represents the total revenue recognized from royalty payments earned through the licensing of intellectual property or drug candidates to third-party partners. It reflects the company's ability to monetize its research and development pipeline by outsourcing commercialization while retaining a percentage of net sales. This is a key indicator of the long-term commercial viability of the company's licensed assets.